{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:17:09Z","timestamp":1793657829117,"version":"4.5.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The interaction between menin and histone-lysine N-methyltransferase 2A (KMT2A) is a critical dependency for KMT2A- or nucleophosmin 1 (NPM1)\u2013altered leukemias and an emerging opportunity for therapeutic development. JNJ-75276617 (bleximenib) is a novel, orally bioavailable, potent, and selective protein-protein interaction inhibitor of the binding between menin and KMT2A. In KMT2A-rearranged (KMT2A-r) and NPM1-mutant (NPM1c) acute myeloid leukemia (AML) cells, JNJ-75276617 inhibited the association of the menin-KMT2A complex with chromatin at target gene promoters, resulting in reduced expression of several menin-KMT2A target genes, including MEIS1 and FLT3. JNJ-75276617 displayed potent antiproliferative activity across several AML and acute lymphoblastic leukemia (ALL) cell lines and patient samples harboring KMT2A or NPM1 alterations in\u00a0vitro. In xenograft models of AML and ALL, JNJ-75276617 reduced leukemic burden and provided a significant dose-dependent survival benefit accompanied by expression changes of menin-KMT2A target genes. JNJ-75276617 demonstrated synergistic effects with gilteritinib in\u00a0vitro in AML cells harboring KMT2A-r. JNJ-75276617 further exhibited synergistic effects with venetoclax and azacitidine in AML cells bearing KMT2A-r in\u00a0vitro, and significantly increased survival in mice. Interestingly, JNJ-75276617 showed potent antiproliferative activity in cell lines engineered with recently discovered mutations (MEN1M327I or MEN1T349M) that developed in patients refractory to the menin-KMT2A inhibitor revumenib. A cocrystal structure of menin in complex with JNJ-75276617 indicates a unique binding mode distinct from other menin-KMT2A inhibitors, including revumenib. JNJ-75276617 is being clinically investigated for acute leukemias harboring KMT2A or NPM1 alterations, as a monotherapy for relapsed\/refractory acute leukemia (NCT04811560), or in combination with AML-directed therapies (NCT05453903).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023022480","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T16:54:46Z","timestamp":1718988886000},"page":"1206-1220","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":82,"title":["Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in\n                    <i>KMT2A<\/i>\n                    - and\n                    <i>NPM1<\/i>\n                    -altered leukemias"],"prefix":"10.1182","volume":"144","author":[{"given":"Min Chul","family":"Kwon","sequence":"first","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem","family":"Thuring","sequence":"additional","affiliation":[{"name":"2Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9115-4360","authenticated-orcid":false,"given":"Olivier","family":"Querolle","sequence":"additional","affiliation":[{"name":"2Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Dai","sequence":"additional","affiliation":[{"name":"3Discovery Product Development and Supply, Janssen R&D, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinne","family":"Verhulst","sequence":"additional","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Pande","sequence":"additional","affiliation":[{"name":"2Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Marien","sequence":"additional","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dries","family":"Goffin","sequence":"additional","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-9104","authenticated-orcid":false,"given":"Daniela V.","family":"Wenge","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"5Division of Hematology\/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4347-3193","authenticated-orcid":false,"given":"Hong","family":"Yue","sequence":"additional","affiliation":[{"name":"6Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"7Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-4292","authenticated-orcid":false,"given":"Jevon A.","family":"Cutler","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"5Division of Hematology\/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Jin","sequence":"additional","affiliation":[{"name":"6Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"7Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-3321","authenticated-orcid":false,"given":"Florian","family":"Perner","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"5Division of Hematology\/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2124-5333","authenticated-orcid":false,"given":"Shanna M.","family":"Hogeling","sequence":"additional","affiliation":[{"name":"8Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Shaffer","sequence":"additional","affiliation":[{"name":"9Discovery Product Development and Supply, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-3943","authenticated-orcid":false,"given":"Frank","family":"Jacobs","sequence":"additional","affiliation":[{"name":"2Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Vinken","sequence":"additional","affiliation":[{"name":"2Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cai","sequence":"additional","affiliation":[{"name":"3Discovery Product Development and Supply, Janssen R&D, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikki","family":"Keersmaekers","sequence":"additional","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filmon","family":"Eyassu","sequence":"additional","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3997-7316","authenticated-orcid":false,"given":"Balpreet","family":"Bhogal","sequence":"additional","affiliation":[{"name":"9Discovery Product Development and Supply, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Verstraeten","sequence":"additional","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"El Ashkar","sequence":"additional","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Perry","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"5Division of Hematology\/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathiba","family":"Jayaguru","sequence":"additional","affiliation":[{"name":"10Translational Research, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Barreyro","sequence":"additional","affiliation":[{"name":"10Translational Research, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kuchnio","sequence":"additional","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Darville","sequence":"additional","affiliation":[{"name":"2Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Krosky","sequence":"additional","affiliation":[{"name":"9Discovery Product Development and Supply, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Urbanietz","sequence":"additional","affiliation":[{"name":"2Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bie","family":"Verbist","sequence":"additional","affiliation":[{"name":"11TMEDS, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Edwards","sequence":"additional","affiliation":[{"name":"9Discovery Product Development and Supply, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn S.","family":"Cowley","sequence":"additional","affiliation":[{"name":"9Discovery Product Development and Supply, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-2361","authenticated-orcid":false,"given":"Robert","family":"Kirkpatrick","sequence":"additional","affiliation":[{"name":"9Discovery Product Development and Supply, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-5793","authenticated-orcid":false,"given":"Ruth","family":"Steele","sequence":"additional","affiliation":[{"name":"9Discovery Product Development and Supply, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucille","family":"Ferrante","sequence":"additional","affiliation":[{"name":"12Early Development, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7759-8213","authenticated-orcid":false,"given":"Christina","family":"Guttke","sequence":"additional","affiliation":[{"name":"10Translational Research, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Daskalakis","sequence":"additional","affiliation":[{"name":"12Early Development, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Christine","family":"Pietsch","sequence":"additional","affiliation":[{"name":"13Discovery Oncology, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"2Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Attar","sequence":"additional","affiliation":[{"name":"10Translational Research, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusri","family":"Elsayed","sequence":"additional","affiliation":[{"name":"13Discovery Oncology, Janssen R&D, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-6306","authenticated-orcid":false,"given":"Eric S.","family":"Fischer","sequence":"additional","affiliation":[{"name":"6Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"7Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-8555","authenticated-orcid":false,"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[{"name":"8Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"5Division of Hematology\/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Packman","sequence":"additional","affiliation":[{"name":"14Early Development, Janssen R&D, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Philippar","sequence":"additional","affiliation":[{"name":"1Discovery Oncology, Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2024101714053248200_bib1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/dmm.015974","article-title":"Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?","volume":"7","author":"Grove","year":"2014","journal-title":"Dis Model Mech"},{"issue":"3","key":"2024101714053248200_bib2","first-page":"33","article-title":"Acute myeloid leukemia: a concise review","volume":"5","author":"Saultz","year":"2016","journal-title":"J\u00a0Clin Med"},{"issue":"11","key":"2024101714053248200_bib3","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","article-title":"Adult acute lymphoblastic leukemia","volume":"91","author":"Paul","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2024101714053248200_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"2024101714053248200_bib5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nm.2305","article-title":"Cancer epigenetics reaches mainstream oncology","volume":"17","author":"Rodriguez-Paredes","year":"2011","journal-title":"Nat Med"},{"issue":"1","key":"2024101714053248200_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"issue":"10","key":"2024101714053248200_bib7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13238-013-3057-2","article-title":"The evolving landscape in the therapy of acute myeloid leukemia","volume":"4","author":"Peloquin","year":"2013","journal-title":"Protein Cell"},{"issue":"4","key":"2024101714053248200_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2018.08.014","article-title":"Prospective isolation and characterization of genetically and functionally distinct AML subclones","volume":"34","author":"de Boer","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"2024101714053248200_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2008.002436","article-title":"The molecular biology of mixed lineage leukemia","volume":"94","author":"Slany","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"2024101714053248200_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"3","key":"2024101714053248200_bib11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/biomedicines11030821","article-title":"Updates in KMT2A gene rearrangement in pediatric acute lymphoblastic leukemia","volume":"11","author":"Gorecki","year":"2023","journal-title":"Biomedicines"},{"issue":"7728","key":"2024101714053248200_bib12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"issue":"4","key":"2024101714053248200_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2024101714053248200_bib14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nat Genet"},{"key":"2024101714053248200_bib15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/asheducation-2013.1.596","article-title":"Treatment of infant leukemias: challenge and promise","volume":"2013","author":"Brown","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2024101714053248200_bib16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.12442","article-title":"Predicting relapse risk in childhood acute lymphoblastic leukaemia","volume":"162","author":"Teachey","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2024101714053248200_bib17","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2024101714053248200_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat Genet"},{"issue":"2","key":"2024101714053248200_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1535-6108(02)00032-6","article-title":"Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling","volume":"1","author":"Yeoh","year":"2002","journal-title":"Cancer Cell"},{"issue":"1","key":"2024101714053248200_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood-2005-01-0204","article-title":"The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy","volume":"106","author":"Whitman","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2024101714053248200_bib21","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2024101714053248200_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2003-06-2163","article-title":"Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies","volume":"103","author":"Poppe","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2024101714053248200_bib23","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1073\/pnas.0510347103","article-title":"The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression","volume":"103","author":"Chen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2024101714053248200_bib24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in\u00a0vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"issue":"6","key":"2024101714053248200_bib25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A\u00a0menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"10","key":"2024101714053248200_bib26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"Kuhn","year":"2016","journal-title":"Cancer Discov"},{"issue":"3","key":"2024101714053248200_bib27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024101714053248200_bib28","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2005-02-0560","article-title":"Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance","volume":"106","author":"Alcalay","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2024101714053248200_bib29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/leu.2011.277","article-title":"Downregulation of MEIS1 impairs long-term expansion of CD34+ NPM1-mutated acute myeloid leukemia cells","volume":"26","author":"Woolthuis","year":"2012","journal-title":"Leukemia"},{"issue":"7954","key":"2024101714053248200_bib30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"7954","key":"2024101714053248200_bib31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"1","key":"2024101714053248200_bib32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12859-019-2975-2","article-title":"Analyzing magnetic bead QuantiGene(R) Plex 2.0 gene expression data in high throughput mode using QGprofiler","volume":"20","author":"Verbist","year":"2019","journal-title":"BMC Bioinf"},{"key":"2024101714053248200_bib33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-1-4939-1133-2_13","article-title":"Ex\u00a0vivo assays to study self-renewal, long-term expansion, and leukemic transformation of genetically modified human hematopoietic and patient-derived leukemic stem cells","volume":"1185","author":"Sontakke","year":"2014","journal-title":"Methods Mol Biol"},{"key":"2024101714053248200_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-59745-418-6_14","article-title":"Ex\u00a0vivo assays to study self-renewal and long-term expansion of genetically modified primary human acute myeloid leukemia stem cells","volume":"538","author":"Schuringa","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"4","key":"2024101714053248200_bib35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4155\/fmc.13.214","article-title":"Challenges and opportunities in targeting the menin-MLL interaction","volume":"6","author":"Cierpicki","year":"2014","journal-title":"Future Med Chem"},{"issue":"21","key":"2024101714053248200_bib36","doi-asserted-by":"crossref","first-page":"15519","DOI":"10.1021\/acs.jmedchem.1c00872","article-title":"Recent progress of small molecule menin-MLL interaction inhibitors as therapeutic agents for acute leukemia","volume":"64","author":"Lei","year":"2021","journal-title":"J\u00a0Med Chem"},{"issue":"5","key":"2024101714053248200_bib37","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2008-01-132316","article-title":"RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia","volume":"113","author":"Kim","year":"2009","journal-title":"Blood"},{"issue":"21","key":"2024101714053248200_bib38","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3\u00a0inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2024101714053248200_bib39","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.2020006575","article-title":"Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations","volume":"136","author":"Miao","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024101714053248200_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-022-00618-4","article-title":"Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/11\/1206\/2247195\/blood_bld-2023-022480-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/11\/1206\/2247195\/blood_bld-2023-022480-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T10:06:06Z","timestamp":1729159566000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/11\/1206\/516663\/Preclinical-efficacy-of-the-potent-selective-menin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022480","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}